



KBMO

DIAGNOSTICS

Metabolic Insights Profile (MIP) Clinical Significance Guide

Reference List



**METABOLIC
INSIGHTS PROFILE**
NEXT GENERATION ORGANIC ACIDS



MICROBIAL METABOLITES



DETOXIFICATION MARKERS



**METABOLISM &
MITOCHONDRIAL MARKERS**



NUTRITION & OXALATES



**NEUROTRANSMITTER
MARKERS**

1. M. Kordowska-Wiater, Production of arabitol by yeasts: current status and future prospects. *J Appl Microbiol* 119, 303–314 (2015).
2. G. C. Bevilaqua, F. Maugeri Filho, M. B. S. Forte, Simultaneous production of xylitol and arabitol by *Candida tropicalis* fermentation improving agro-industrial wastes valorization. *Food and Bioproducts Processing* 140, 29–45 (2023).
3. M. Amaha, T. Sai, Some aspects of (–)-citramalic acid accumulation by respiration-deficient mutants of yeasts. *Antonie Van Leeuwenhoek* 35, Suppl:G15–16 (1969).
4. L. Zhang, D. L. Li, Y. C. Chen, M. H. Tao, W. M. Zhang, [Study on secondary metabolites of marine fungus *Penicillium* sp. FS60 from the South China Sea]. *Zhong Yao Cai* 35, 1091–1094 (2012).
5. M. Pratt-Hyatt, Biochemical Markers in the Urine Associated with Gastrointestinal Mold-Overgrowth Are Linked with Elevated Urinary Mycotoxins in Patients with Suspected Mold Illness. *Townsend Letter* 31 (2019).
6. R. O. Rajesh et al., Biosynthesis of 2,5-furan dicarboxylic acid by *Aspergillus flavus* APLS-1: Process optimization and intermediate product analysis. *Bioresour Technol* 284, 155–160 (2019).
7. Y. Lia et al., Tricarballic ester formation during biosynthesis of fumonisin mycotoxins in *Fusarium verticillioides*. *Mycology* 4, 179–186 (2013).
8. J. McDevitt, P. Goldman, Effect of the intestinal flora on the urinary organic acid profile of rats ingesting a chemically simplified diet. *Food Chem Toxicol* 29, 107–113 (1991).
9. M. Zhou, Y. Bi, M. Ding, Y. Yuan, One-Step Biosynthesis of Vitamin C in *Saccharomyces cerevisiae*. *Front Microbiol* 12, 643472 (2021).
10. S. Reichheld, T. M. Finan, "Vitamins" in *Encyclopedia of Genetics*, S. Brenner, J. H. Miller, Eds. (Academic Press, New York, 2001), <https://doi.org/10.1006/rwgn.2001.1374>, pp. 2117–2120.
11. A. Boverio et al., Structure, mechanism, and evolution of the last step in vitamin C biosynthesis. *Nat Commun* 15, 4158 (2024).
12. X. Xiong, D. Liu, Y. Wang, T. Zeng, Y. Peng, Urinary 3-(3-Hydroxyphenyl)-3-hydroxypropionic Acid, 3-Hydroxyphenylacetic Acid, and 3-Hydroxyhippuric Acid Are Elevated in Children with Autism Spectrum Disorders. *Biomed Res Int* 2016, 9485412 (2016).
13. W. Shaw, Increased urinary excretion of a 3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HPHPA), an abnormal phenylalanine metabolite of *Clostridia* spp. in the gastrointestinal tract, in urine samples from patients with autism and schizophrenia. *Nutr Neurosci* 13, 135–143 (2010).
14. F. Blachier, M. Andriamihaja, Effects of the L-tyrosine-derived bacterial metabolite p-cresol on colonic and peripheral cells. *Amino Acids* 54, 325–338 (2022).
15. S. P. Couvillion et al., Graphene oxide exposure alters gut microbial community composition and metabolism in an in vitro human model. *NanoImpact* 30, 100463 (2023).
16. A. Temellini et al., Conjugation of benzoic acid with glycine in human liver and kidney: a study on the interindividual variability. *Xenobiotica* 23, 1427–1433 (1993).
17. C. van der Heiden, E. A. Wauters, M. Duran, S. K. Wadman, D. Ketting, Gas chromatographic analysis of urinary tyrosine and phenylalanine metabolites in patients with gastrointestinal disorders. *Clin Chim Acta* 34, 289–296 (1971).

18. A. Ticinesi, A. Guerra, A. Nouvenne, T. Meschi, S. Maggi, Disentangling the Complexity of Nutrition, Frailty and Gut Microbial Pathways during Aging: A Focus on Hippuric Acid. *Nutrients* 15 (2023).
19. J. L. Barker, J. W. Frost, Microbial synthesis of p-hydroxybenzoic acid from glucose. *Biotechnol Bioeng* 76, 376–390 (2001).
20. R. A. Chalmers, H. B. Valman, M. M. Liberman, Measurement of 4-hydroxyphenylacetic aciduria as a screening test for small-bowel disease. *Clin Chem* 25, 1791–1794 (1979).
21. P. D. Sobolev, N. A. Burnakova, N. V. Beloborodova, A. I. Revelsky, A. K. Pautova, Analysis of 4-Hydroxyphenyllactic Acid and Other Diagnostically Important Metabolites of alpha-Amino Acids in Human Blood Serum Using a Validated and Sensitive Ultra-High-Pressure Liquid Chromatography–Tandem Mass Spectrometry Method. *Metabolites* 13 (2023).
22. I. Dominguez-Lopez et al., Urinary Tartaric Acid, a Biomarker of Wine Intake, Correlates with Lower Total and LDL Cholesterol. *Nutrients* 13 (2021).
23. M. Rosenberg, L. Kristofikova, E. Sturdik, Influence of carbohydrates and polyols on L-lactic acid production and fatty acid formation by *Rhizopus arrhizus*. *World J Microbiol Biotechnol* 10, 271–274 (1994).
24. M. Fukuchi, M. Sugita, M. Banjo, K. Yonekura, Y. Sasuga, The impact of a competitive event and the efficacy of a lactic acid bacteria-fermented soymilk extract on the gut microbiota and urinary metabolites of endurance athletes: An open-label pilot study. *PLoS One* 17, e0262906 (2022).
25. Y. Gamarra et al., Pyroglutamic acidosis by glutathione regeneration blockage in critical patients with septic shock. *Crit Care* 23, 162 (2019).
26. A. A. Jackson, C. Persaud, T. S. Meakins, R. Bundy, Urinary excretion of 5-L-oxoproline (pyroglutamic acid) is increased in normal adults consuming vegetarian or low protein diets. *J Nutr* 126, 2813–2822 (1996).
27. A. Dinescu, T. R. Cundari, V. S. Bhansali, J. L. Luo, M. E. Anderson, Function of conserved residues of human glutathione synthetase: implications for the ATP-grasp enzymes. *J Biol Chem* 279, 22412–22421 (2004).
28. A. Manoharan et al., N-Acetylcysteine Protects Bladder Epithelial Cells from Bacterial Invasion and Displays Antibiofilm Activity against Urinary Tract Bacterial Pathogens. *Antibiotics (Basel)* 10 (2021).
29. K. R. Atkuri, J. J. Mantovani, L. A. Herzenberg, L. A. Herzenberg, N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency. *Curr Opin Pharmacol* 7, 355–359 (2007).
30. H. Arab, S. Mahjoub, K. Hajian-Tilaki, M. Moghadasi, The effect of green tea consumption on oxidative stress markers and cognitive function in patients with Alzheimer's disease: A prospective intervention study. *Caspian J Intern Med* 7, 188–194 (2016).
31. B. Dorcely et al., Novel biomarkers for prediabetes, diabetes, and associated complications. *Diabetes Metab Syndr Obes* 10, 345–361 (2017).
32. B. Suh et al., A new HPLC analytical method for o-hydroxyhippuric acid in uremic serum. *J Biochem Biophys Methods* 13, 211–220 (1986).
33. H. Goldberg, L. Grass, R. Vogl, A. Rapoport, D. G. Oreopoulos, Urine citrate and renal stone disease. *CMAJ* 141, 217–221 (1989).
34. Q. Chen, Y. Qiao, X. J. Xu, X. You, Y. Tao, Urine Organic Acids as Potential Biomarkers for Autism-Spectrum Disorder in Chinese Children. *Front Cell Neurosci* 13, 150 (2019).

35. J. H. Haam et al., Elevated levels of urine isocitrate, hydroxymethylglutarate, and formiminoglutamate are associated with arterial stiffness in Korean adults. *Sci Rep* 11, 10180 (2021).
36. E. A. Struys, K. M. Gibson, C. Jakobs, Novel insights into L-2-hydroxyglutaric aciduria: mass isotopomer studies reveal 2-oxoglutaric acid as the metabolic precursor of L-2-hydroxyglutaric acid. *J Inherit Metab Dis* 30, 690–693 (2007).
37. M. Wang et al., Calcium-deficiency assessment and biomarker identification by an integrated urinary metabolomics analysis. *BMC Med* 11, 86 (2013).
38. L. Tretter, V. Adam-Vizi, Alpha-ketoglutarate dehydrogenase: a target and generator of oxidative stress. *Philos Trans R Soc Lond B Biol Sci* 360, 2335–2345 (2005).
39. F. Bouillaud, Inhibition of Succinate Dehydrogenase by Pesticides (SDHIs) and Energy Metabolism. *Int J Mol Sci* 24 (2023).
40. R. A. Harris, M. Joshi, N. H. Jeoung, M. Obayashi, Overview of the molecular and biochemical basis of branched-chain amino acid catabolism. *J Nutr* 135, 1527S–1530S (2005).
41. D. Tsoukalas et al., Prediction of Autoimmune Diseases by Targeted Metabolomic Assay of Urinary Organic Acids. *Metabolites* 10 (2020).
42. G. Allegri et al., Fumaric aciduria: an overview and the first Brazilian case report. *J Inherit Metab Dis* 33, 411–419 (2010).
43. Y. P. Wang et al., Malic enzyme 2 connects the Krebs cycle intermediate fumarate to mitochondrial biogenesis. *Cell Metab* 33, 1027–1041 e1028 (2021).
44. S. R. Pieczenik, J. Neustadt, Mitochondrial dysfunction and molecular pathways of disease. *Exp Mol Pathol* 83, 84–92 (2007).
45. O. A. Rotimi et al., Acute aflatoxin B1 - Induced hepatotoxicity alters gene expression and disrupts lipid and lipoprotein metabolism in rats. *Toxicol Rep* 4, 408–414 (2017).
46. R. Gonzalez-Dominguez et al., Mechanistic Insights into Alzheimer's Disease Unveiled through the Investigation of Disturbances in Central Metabolites and Metabolic Pathways. *Biomedicines* 9 (2021).
47. M. Oresic et al., Targeted Serum Metabolite Profiling Identifies Metabolic Signatures in Patients with Alzheimer's Disease, Normal Pressure Hydrocephalus and Brain Tumor. *Front Neurosci* 11, 747 (2017).
48. J. E. Pettersen, E. Jellum, L. Eldjarn, The occurrence of adipic and suberic acid in urine from ketotic patients. *Clin Chim Acta* 38, 17–24 (1972).
49. M. Duran, F. J. Walther, L. Bruinvis, S. K. Wadman, The urinary excretion of ethylmalonic acid: what level requires further attention? *Biochem Med* 29, 171–175 (1983).
50. P. D. Lohano, M. Ibrahim, S. J. Raza, M. Gowa, S. H. Baloch, Comparing Finger-stick Betaeta-hydroxybutyrate with Dipstick Urine Tests in the Detection of Ketone Bodies in the Diagnosis of Children with Diabetic Ketoacidosis. *J Coll Physicians Surg Pak* 32, 483–486 (2022).
51. E. A. Nyenwe, A. E. Kitabchi, The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management. *Metabolism* 65, 507–521 (2016).
52. M. A. Ciorba, Kynurenine pathway metabolites: relevant to vitamin B-6 deficiency and beyond. *Am J Clin Nutr* 98, 863–864 (2013).

53. J. Kelsay, A. Baysal, H. Linkswiler, Effect of vitamin B6 depletion on the pyridoxal, pyridoxamine and pyridoxine content of the blood and urine of men. *J Nutr* 94, 490-494 (1968).
54. P. M. Coates, Paul, M.C., Blackman, M., Blackman, M.R., Cragg, G.M., Levine, M., White, J.D., & Moss, J. (Eds.). (2004). *Encyclopedia of Dietary Supplements* (Online) (1st ed.). CRC Press. <https://doi.org/10.1201/b13959>.
55. S. Kolker et al., Diagnosis and management of glutaric aciduria type I--revised recommendations. *J Inherit Metab Dis* 34, 677-694 (2011).
56. P. T. Lascelles, D. Donaldson, "Formiminoglutamic Acid (FIGLU) Test" in *Diagnostic Function Tests in Chemical Pathology*. (Springer Netherlands, Dordrecht, 1989), 10.1007/978-94-009-1846-7_31, pp. 59-60.
57. T. Kwok et al., Use of fasting urinary methylmalonic acid to screen for metabolic vitamin B12 deficiency in older persons. *Nutrition* 20, 764-768 (2004).
58. K. J. Van Acker, F. J. Eyskens, R. M. Verkerk, S. S. Scharpe, Urinary excretion of purine and pyrimidine metabolites in the neonate. *Pediatr Res* 34, 762-766 (1993).
59. A. H. van Gennip, N. G. Abeling, P. Vreken, A. B. van Kuilenburg, Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects. *J Inherit Metab Dis* 20, 203-213 (1997).
60. L. K. Massey, H. Roman-Smith, R. A. Sutton, Effect of dietary oxalate and calcium on urinary oxalate and risk of formation of calcium oxalate kidney stones. *J Am Diet Assoc* 93, 901-906 (1993).
61. Z. Li et al., A study of organic acid production in contrasts between two phosphate solubilizing fungi: *Penicillium oxalicum* and *Aspergillus niger*. *Sci Rep* 6, 25313 (2016).
62. E. Leumann, B. Hoppe, T. Neuhaus, Management of primary hyperoxaluria: efficacy of oral citrate administration. *Pediatr Nephrol* 7, 207-211 (1993).
63. D. J. Dietzen et al., Extraction of glyceric and glycolic acids from urine with tetrahydrofuran: utility in detection of primary hyperoxaluria. *Clin Chem* 43, 1315-1320 (1997).
64. S. B. Wortmann, L. A. Kluijtmans, U. F. Engelke, R. A. Wevers, E. Morava, The 3-methylglutaconic acidurias: what's new? *J Inherit Metab Dis* 35, 13-22 (2012).
65. A. Jennings, A. MacGregor, T. Pallister, T. Spector, A. Cassidy, Associations between branched chain amino acid intake and biomarkers of adiposity and cardiometabolic health independent of genetic factors: A twin study. *Int J Cardiol* 223, 992-998 (2016).
66. M. Tuchman, M. T. McCann, P. E. Johnson, B. Lemieux, Screening newborns for multiple organic acidurias in dried filter paper urine samples: method development. *Pediatr Res* 30, 315-321 (1991).
67. W. Lehnert, A. Junker, [2-Methyl-3-oxovaleric acid: a characteristic metabolite in propionic acidemia]. *Clin Chim Acta* 104, 47-51 (1980).
68. S. Funghini et al., 3-Hydroxy-3-methylglutaric aciduria in an Italian patient is caused by a new nonsense mutation in the HMGCL gene. *Mol Genet Metab* 73, 268-275 (2001).
69. K. Folkers et al., Lovastatin decreases coenzyme Q levels in humans. *Proc Natl Acad Sci U S A* 87, 8931-8934 (1990).
70. M. E. Brosnan, J. T. Brosnan, Orotic acid excretion and arginine metabolism. *J Nutr* 137, 1656S-1661S (2007).

References

71. M. M. Wamelink et al., 4-Hydroxybutyric aciduria associated with catheter usage: a diagnostic pitfall in the identification of SSADH deficiency. *Mol Genet Metab* 102, 216–217 (2011).
72. T. Kuhara et al., Studies of urinary organic acid profiles of a patient with dihydrolipoyl dehydrogenase deficiency. *Clin Chim Acta* 133, 133–140 (1983).
73. C. Jakobs et al., Stable isotope dilution analysis of orotic acid and uracil in amniotic fluid. *Clin Chim Acta* 143, 123–133 (1984).
74. E. M. Mathew et al., Novel HILIC-ESI-MS method for urinary profiling of MSUD and methylmalonic aciduria biomarkers. *J Chromatogr Sci* 57, 715–723 (2019).
75. D. F. Davidson, Elevated urinary dopamine in adults and children. *Ann Clin Biochem* 42, 200–207 (2005).
76. M. Matsuo, R. Tasaki, H. Kodama, Y. Hamasaki, Screening for Menkes disease using the urine HVA/VMA ratio. *J Inher Metab Dis* 28, 89–93 (2005).
77. J. R. Lenchner, C. Santos, "Biochemistry, 5 Hydroxyindoleacetic Acid" in StatPearls. (Treasure Island (FL), 2025).
78. E. Wirthgen, A. Hoeflich, A. Rebl, J. Gunther, Kynurenic Acid: The Janus-Faced Role of an Immunomodulatory Tryptophan Metabolite and Its Link to Pathological Conditions. *Front Immunol* 8, 1957 (2017).
79. D. P. Rose, P. A. Toseland, Urinary excretion of quinolinic acid and other tryptophan metabolites after deoxypridoxine or oral contraceptive administration. *Metabolism* 22, 165–171 (1973).
80. M. A. Sofia et al., Tryptophan Metabolism through the Kynurenine Pathway is Associated with Endoscopic Inflammation in Ulcerative Colitis. *Inflamm Bowel Dis* 24, 1471–1480 (2018).
81. S. J. Brown, X. F. Huang, K. A. Newell, The kynurenine pathway in major depression: What we know and where to next. *Neurosci Biobehav Rev* 127, 917–927 (2021).
82. K. M. O'Brien, K. Upson, N. R. Cook, C. R. Weinberg, Environmental Chemicals in Urine and Blood: Improving Methods for Creatinine and Lipid Adjustment. *Environ Health Perspect* 124, 220–227 (2016).



METABOLIC INSIGHTS PROFILE

NEXT GENERATION ORGANIC ACIDS

CONTACT INFORMATION



1+ 617.933.8130



info@kbmodiagnostics.com



www.kbmodiagnostics.com

SCAN FOR MORE INFORMATION



SAMPLE REPORT



COLLECTION
INSTRUCTIONS



COLLECTION
INSTRUCTIONS
VIDEO

KBMO'S MIP CAN HELP IN IDENTIFYING:

- Microbiome Imbalances
- Fungal Colonization
- Malnutrition
- Autoimmune Diseases
- Metabolic Disorders
- Detoxification Processes
- PANS / PANDAS
- Neurological Disorders
- Memory Retention
- Depression / Anxiety
- Cardiovascular Disease
- Oxidative Stress
- Energy Production
- ... and much more

SAMPLE INFORMATION

Requirements: 5 ml first morning urine

Turn around time: 7-10 business days

Reporting method:
Practitioner's portal,
interactive report, printable
PDF



KBMO Diagnostics is scientist developed and owned, and committed to providing the highest quality testing services to ensure your patients receive the best care possible.



KBMO

DIAGNOSTICS